Publicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (9)

2024

  1. Corrigendum: Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries (Front. Med., 11, (1439338), (10.3389/fmed.2024.1439338))

    Frontiers in Medicine

  2. Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries

    Frontiers in Medicine, Vol. 11

  3. Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study

    Eye (Basingstoke)

  4. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration

    Ophthalmology Retina, Vol. 8, Núm. 4, pp. 350-359

  5. Protocolo de tratamiento del edema macular quístico asociado a retinosis pigmentaria y otras distrofias hereditarias de la retina

    Archivos de la Sociedad Española de Oftalmologia, Vol. 99, Núm. 2, pp. 67-81

2022

  1. Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry

    Ophthalmology Retina, Vol. 6, Núm. 11, pp. 1044-1053

2020

  1. Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study

    Acta Ophthalmologica, Vol. 98, Núm. 7, pp. e820-e829

2019

  1. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases

    Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089

2018

  1. Efficacy and safety of an aflibercept treat-and-extend regimen in treatment-naïve patients with macular oedema secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial

    Journal of Ophthalmology, Vol. 2018